Safety and Efficacy of Brimonidine in Patients With Glaucoma or Ocular Hypertension

Phase 3

Completed

• Conditions: Glaucoma; Ocular Hypertension

• Registration Number: NCT00168363
• Lead Sponsor: Allergan

Brief Summary

This Study will evaluate the safety and efficacy of brimonidine in patients with glaucoma or ocular hypertension

Detailed Description

Not available

Study Timeline

• Study Start: 2005-01
• Study First Submitted: 2005-09-12
• Study First Submitted QC: 2005-09-12
• Study First Posted: 2005-09-15
• Primary Completion: 2006-08
• Study Completion: 2006-08
• Status Verified: 2011-05
• Last Update Submitted: 2011-05-27
• Last Update Posted: 2011-05-30

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 207

Inclusion Criteria

• ocular hypertension or glaucoma in both eyes
• currently treated with brimonidine
• requires IOP-lowering therapy in both eyes

Exclusion Criteria

• uncontrolled systemic disease
• known allergy or sensitivity to brimonidine

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
lowering of intraocular pressure